Comments
Dr Reddy’s Laboratories on Wednesday announced the launch of its Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz Injection, approved by the US Food and Drug Administration.
The Bloxiverz brand and generic had US sales of approximately $111 million (MAT) for the most recent 12 months ending in July 2018, according to IMS Health. Dr Reddy’s injection will be available in 5 mg/10 ml and 10mg/10 ml multi-dose vials.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.